Utilized for colorectal and breast cancer to target malignant cells and support oncology treatment goals.
Mechanism of Action
This prodrug is enzymatically converted to 5-fluorouracil within the body, particularly in tumor cells. It inhibits thymidylate synthase and incorporates into RNA, leading to DNA damage and inhibition of cancer cell proliferation.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
Variable
Contraindications
Severe renal impairment, Hypersensitivity to capecitabine, Hypersensitivity to fluorouracil, Dihydropyrimidine dehydrogenase deficiency
Severe Adverse Events
Myelosuppression, Cardiotoxicity, Severe dehydration — requires immediate medical attention
Information related to Capecitabine is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
